Akoya Biosciences (AKYA) News Today $2.82 +0.06 (+2.17%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Akoya Biosciences (NASDAQ:AKYA) Stock Rating Lowered by Canaccord Genuity GroupCanaccord Genuity Group downgraded shares of Akoya Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Monday.January 15, 2025 | marketbeat.comQuanterix price target lowered to $11 from $15 at TD CowenJanuary 13, 2025 | markets.businessinsider.comHold Rating Suggested Amid Acquisition Uncertainties and Growth Concerns for Akoya BiosciencesJanuary 13, 2025 | markets.businessinsider.comAkoya Biosciences (NASDAQ: AKYA) Enters Merger Agreement with Quanterix CorporationJanuary 13, 2025 | americanbankingnews.comQTRX-Akoya Acquisition: Cautious Hold Amid Strategic Synergy and Integration UncertaintiesJanuary 11, 2025 | markets.businessinsider.comAkoya Biosciences Inc AKYAJanuary 11, 2025 | morningstar.comAKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya ...January 10, 2025 | businesswire.comAKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYAJanuary 10, 2025 | businesswire.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Akoya Biosciences, Inc. BuyoutJanuary 10, 2025 | markets.businessinsider.comAKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. ...January 10, 2025 | gurufocus.comQuanterix Agrees to Buy Life Sciences Firm Akoya BiosciencesJanuary 10, 2025 | msn.comTraders Digest Strong Jobs Growth as US Equity Futures Drop Pre-BellJanuary 10, 2025 | msn.comAkoya climbs after merger deal with QuanterixJanuary 10, 2025 | seekingalpha.comAKYA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akoya Biosciences, Inc. Is Fair to ShareholdersJanuary 10, 2025 | tmcnet.comQuanterix To Buy Akoya Biosciences In All Stock Deal; QTRX Up In Pre-MarketJanuary 10, 2025 | markets.businessinsider.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Rating of "Hold" by AnalystsShares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) have been given an average recommendation of "Hold" by the seven research firms that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating and three have assigned a buy raDecember 30, 2024 | marketbeat.comShort Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Expands By 20.7%Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 1,810,000 shares, an increase of 20.7% from the November 30th total of 1,500,000 shares. Approximately 9.1% of the shares of the stock are short sold. Based on an average daily volume of 229,100 shares, the days-to-cover ratio is presently 7.9 days.December 29, 2024 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 18.1% in NovemberAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 1,500,000 shares, an increase of 18.1% from the November 15th total of 1,270,000 shares. Based on an average daily volume of 228,600 shares, the short-interest ratio is currently 6.6 days. Currently, 7.5% of the shares of the stock are sold short.December 14, 2024 | marketbeat.comAkoya Biosciences, NeraCare enter exclusive global license agreementDecember 11, 2024 | markets.businessinsider.comAkoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment DecisionsDecember 10, 2024 | globenewswire.comNature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry MilestoneDecember 10, 2024 | markets.businessinsider.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Recommendation of "Hold" from BrokeragesAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) has earned an average rating of "Hold" from the eight analysts that are covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-December 5, 2024 | marketbeat.comAkoya Biosciences (NASDAQ:AKYA) Given "Overweight" Rating at Piper SandlerPiper Sandler reiterated an "overweight" rating and issued a $3.00 price target (down from $4.00) on shares of Akoya Biosciences in a research note on Tuesday.November 19, 2024 | marketbeat.comTime To Worry? Analysts Just Downgraded Their Akoya Biosciences, Inc. (NASDAQ:AKYA) OutlookNovember 17, 2024 | finance.yahoo.comCraig-Hallum Downgrades Akoya Biosciences (AKYA)November 16, 2024 | msn.comAkoya Biosciences Shares Sink After FY24 Outlook CutNovember 15, 2024 | marketwatch.comAkoya Biosciences Inc (AKYA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...November 15, 2024 | finance.yahoo.comAkoya Biosciences Reports Q3 2024 Financial ResultsNovember 15, 2024 | markets.businessinsider.comAkoya Biosciences downgraded to Hold from Buy at Craig-HallumNovember 15, 2024 | markets.businessinsider.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | msn.comCanaccord Genuity Group Has Lowered Expectations for Akoya Biosciences (NASDAQ:AKYA) Stock PriceCanaccord Genuity Group dropped their price target on Akoya Biosciences from $6.00 to $3.50 and set a "buy" rating on the stock in a research report on Friday.November 15, 2024 | marketbeat.comAkoya Biosciences (NASDAQ:AKYA) Stock Rating Lowered by Craig HallumCraig Hallum lowered Akoya Biosciences from a "buy" rating to a "hold" rating and reduced their price target for the stock from $7.00 to $5.00 in a research report on Friday.November 15, 2024 | marketbeat.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Sees Large Decline in Short InterestAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the recipient of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 1,600,000 shares, a decline of 20.8% from the October 15th total of 2,020,000 shares. Approximately 7.8% of the company's shares are short sold. Based on an average trading volume of 132,000 shares, the short-interest ratio is currently 12.1 days.November 15, 2024 | marketbeat.comAkoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comAkoya Biosciences Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | globenewswire.comCraig-Hallum Sticks to Its Buy Rating for Akoya Biosciences (AKYA)November 12, 2024 | markets.businessinsider.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Recommendation of "Moderate Buy" by AnalystsAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) has earned an average rating of "Moderate Buy" from the nine research firms that are presently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and five have assigned a buy recommendatioNovember 10, 2024 | marketbeat.comAkoya Biosciences (AKYA) Scheduled to Post Quarterly Earnings on ThursdayAkoya Biosciences (NASDAQ:AKYA) will be releasing earnings after the market closes on Thursday, November 14, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=640894)November 7, 2024 | marketbeat.comAkoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO PanelNovember 6, 2024 | markets.businessinsider.comAkoya Biosciences unveils new era in spatial content innovationNovember 6, 2024 | markets.businessinsider.comAkoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024October 28, 2024 | globenewswire.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine research firms that are presently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and fivOctober 16, 2024 | marketbeat.comAkoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer ImmunotherapyOctober 9, 2024 | markets.businessinsider.comAkoya Biosciences (NASDAQ:AKYA) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comAkoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer ImmunotherapyOctober 7, 2024 | globenewswire.comAkoya Biosciences Announces Appointment Of Scott Mendel As Chairman Of The Board Of DirectorsOctober 3, 2024 | markets.businessinsider.comAkoya Biosciences Announces Scott Mendel as Chairman of the Board of DirectorsOctober 3, 2024 | globenewswire.comShort Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Declines By 6.4%Akoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 3,090,000 shares, a decrease of 6.4% from the August 31st total of 3,300,000 shares. Currently, 14.0% of the company's stock are sold short. Based on an average daily volume of 182,500 shares, the short-interest ratio is presently 16.9 days.September 30, 2024 | marketbeat.comCraig-Hallum Reaffirms Their Buy Rating on Akoya Biosciences (AKYA)September 14, 2024 | markets.businessinsider.comAkoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 6.3% in AugustAkoya Biosciences, Inc. (NASDAQ:AKYA - Get Free Report) saw a large increase in short interest in August. As of August 15th, there was short interest totalling 3,360,000 shares, an increase of 6.3% from the July 31st total of 3,160,000 shares. Currently, 15.2% of the company's stock are sold short. Based on an average trading volume of 272,000 shares, the short-interest ratio is presently 12.4 days.September 2, 2024 | marketbeat.com Get Akoya Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter. Email Address AKYA Media Mentions By Week AKYA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKYA News Sentiment▼0.000.46▲Average Medical News Sentiment AKYA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKYA Articles This Week▼22▲AKYA Articles Average Week Get Akoya Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EYPT News Today SENS News Today ALNT News Today AEHR News Today QTRX News Today QSI News Today NAUT News Today KEQU News Today FEIM News Today SEER News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKYA) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akoya Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akoya Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.